High sensitivity cardiac troponin assays in the clinical laboratories

Clinical Chemistry and Laboratory Medicine

Volumn 53, Issue 5, 2015, Pages 635-652

  Jarolim, Petr ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

acute myocardial infarction; cardiac troponin I; cardiac troponin T; diagnosis; high sensitivity assay; prognosis; ultrasensitive assay

Indexed keywords

TROPONIN I; TROPONIN T; TROPONIN;

ACUTE HEART INFARCTION; CARDIOVASCULAR DIAGNOSTIC DEVICE; CARDIOVASCULAR DISEASE; CLINICAL LABORATORY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; END STAGE RENAL DISEASE; HEART FAILURE; HIGH RISK PATIENT; HUMAN; IMMUNOASSAY; MEASUREMENT ACCURACY; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY; CLINICAL CHEMISTRY; HEART MUSCLE; LIMIT OF DETECTION; METABOLISM; PROCEDURES; STANDARDS;

CLINICAL CHEMISTRY TESTS; HUMANS; LIMIT OF DETECTION; MYOCARDIUM; PROGNOSIS; TROPONIN;

EID: 84928019907     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2014-0565     Document Type: Review

References (111)

1. Parmacek MS, Solaro RJ. Biology of the troponin complex in cardiac myocytes. Prog Cardiovasc Dis 2004;47:159-76.
2. Wilkinson J, Grand R. Comparison of amino acid sequence of troponin I from different striated muscles. Nature 1978;271:31-5.
3. Perry SV. Troponin T: genetics, properties and function. J Muscle Res Cell Motil 1998;19:575-602.
4. Cullen ME, Dellow KA, Barton PJ. Structure and regulation of human troponin genes. Mol Cell Biochem 2004;263:81-90.
5. Willott RH, Gomes AV, Chang AN, Parvatiyar MS, Pinto JR, Potter JD. Mutations in troponin that cause HCM, DCM AND RCM: what can we learn about thin filament function? J Mol Cell Cardiol 2010;48:882-92.
6. Sasse S, Brand NJ, Kyprianou P, Dhoot GK, Wade R, Arai M, et al. Troponin I gene expression during human cardiac development and in end-stage heart failure. Circ Res 1993;72:932-8.
7. Bhavsar PK, Dhoot GK, Cumming DV, Butler-Browne GS, Yacoub MH, Barton PJ. Developmental expression of troponin I isoforms in fetal human heart. FEBS Lett 1991;292:5-8.
8. Jaffe AS, Vasile VC, Milone M, Saenger AK, Olson KN, Apple FS. Diseased skeletal muscle a noncardiac source of increased circulating concentrations of cardiac troponin T. J Am Coll Cardiol 2011;58:1819-24.
9. Agewall S. Increases of creatine kinase MB and cardiac troponin T in serum of a patient with uterine leiomyosarcoma. Clin Chem 2000;46:2016-7.
10. Michele DE, Albayya FP, Metzger JM. Thin filament protein dynamics in fully differentiated adult cardiac myocytes: toward a model of sarcomere maintenance. J Cell Biol 1999;145:1483-95.
11. Martin AF. Turnover of cardiac troponin subunits. Kinetic evidence for a precursor pool of troponin-I. J Biol Chem 1981;256:964-8.
12. Streng AS, de Boer D, van der Velden J, van Dieijen-Visser MP, Wodzig WK. Posttranslational modifications of cardiac troponin T: an overview. J Mol Cell Cardiol 2013;63:47-56.
13. Solaro RJ, Henze M, Kobayashi T. Integration of troponin I phosphorylation with cardiac regulatory networks. Circ Res 2013;112:355-66.
14. Giannitsis E, Katus HA. Cardiac troponin level elevations not related to acute coronary syndromes. Nat Rev Cardiol 2013;10:623-34.
15. Hickman PE, Potter JM, Aroney C, Koerbin G, Southcott E, Wu AH, et al. Cardiac troponin may be released by ischemia alone, without necrosis. Clin Chim Acta 2010;411:318-23.
16. Bergmann O, Bhardwaj RD, Bernard S, Zdunek S, Barnabé- Heider F, Walsh S, et al. Evidence for cardiomyocyte renewal in humans. Science 2009;324:98-102.
17. Katrukha AG, Bereznikova AV, Filatov VL, Esakova TV, Kolosova OV, Pettersson K, et al. Degradation of cardiac troponin I: implication for reliable immunodetection. Clin Chem 1998;44:2433-40.
18. Katrukha IA. Human cardiac troponin complex. Structure and functions. Biochem 2013;78:1447-65.
19. Müller-Bardorff M, Weidtmann B, Giannitsis E, Kurowski V, Katus HA. Release kinetics of cardiac troponin T in survivors of confirmed severe pulmonary embolism. Clin Chem 2002;48:673-5.
20. Wiessner R, Hannemann-Pohl K, Ziebig R, Grubitzsch H, Hocher B, Vargas-Hein O, et al. Impact of kidney function on plasma troponin concentrations after coronary artery bypass grafting. Nephrol Dial Transplant 2008;23:231-8.
21. Lippi G, Cervellin G. High-sensitivity troponin T is more susceptible than high-sensitivity troponin I to impaired renal function. Am J Cardiol 2013;112:1985.
22. Pfortmueller CA, Funk G-C, Marti G, Leichtle AB, Fiedler GM, Schwarz C, et al. Diagnostic performance of high-sensitive troponin T in patients with renal insufficiency. Am J Cardiol 2013;112:1968-72.
23. Hassan HC, Howlin K, Jefferys A, Spicer ST, Aravindan AN, Suryanarayanan G, et al. High-sensitivity troponin as a predictor of cardiac events and mortality in the stable dialysis population. Clin Chem 2014;60:389-98.
24. Cummins B, Auckland ML, Cummins P. Cardiac-specific troponin-I radioimmunoassay in the diagnosis of acute myocardial infarction. Am Heart J 1987;113:1333-44.
25. Katus HA, Remppis A, Looser S, Hallermeier K, Scheffold T, Kübler W. Enzyme linked immuno assay of cardiac troponin T for the detection of acute myocardial infarction in patients. J Mol Cell Cardiol 1989;21:1349-53.
26. Apple FS. A new season for cardiac troponin assays: it's time to keep a scorecard. Clin Chem 2009;55:1303-6.
27. Keller T, Münzel T, Blankenberg S. Making it more sensitive: the new era of troponin use. Circulation 2011;123:1361-3.
28. Wu AH, Christenson RH. Analytical and assay issues for use of cardiac troponin testing for risk stratification in primary care. Clin Biochem 2013;46:969-78.
29. Apple FS, Collinson PO. Analytical characteristics of high-sensitivity cardiac troponin assays. Clin Chem 2012;58:54-61.
30. Saenger AK, Beyrau R, Braun S, Cooray R, Dolci A, Freidank H, et al. Multicenter analytical evaluation of a high-sensitivity troponin T assay. Clin Chim Acta 2011;412:748-54.
31. Krintus M, Kozinski M, Boudry P, Capell NE, Köller U, Lackner K, et al. European multicenter analytical evaluation of the Abbott ARCHITECT STAT high sensitive troponin I immunoassay. Clin Chem Lab Med 2014;52:1657-65.
32. Roziakova L, Bojtarova E, Mistrik M, Dubrava J, Gergel J, Lenkova N, et al. Serial measurements of cardiac biomarkers in patients after allogeneic hematopoietic stem cell transplantation. J Exp Clin Cancer Res 2012;31:13.
33. Todd J, Freese B, Lu A, Held D, Morey J, Livingston R, et al. Ultrasensitive flow-based immunoassays using single-molecule counting. Clin Chem 2007;53:1990-5.
34. Wilson SR, Sabatine MS, Braunwald E, Sloan S, Murphy SA, Morrow DA. Detection of myocardial injury in patients with unstable angina using a novel nanoparticle cardiac troponin I assay: observations from the PROTECT-TIMI 30 Trial. Am Heart J 2009;158:386-91.
35. Rissin DM, Kan CW, Campbell TG, Howes SC, Fournier DR, Song L, et al. Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat Biotechnol 2010;28:595-9.
36. Kan CW, Rivnak AJ, Campbell TG, Piech T, Rissin DM, Mösl M, et al. Isolation and detection of single molecules on paramagnetic beads using sequential fluid flows in microfabricated polymer array assemblies. Lab Chip 2012;12:977-85.
37. IFCC. Analytical characteristics of commercial and research cardiac troponin I and T assays declared by the manufacturer [Internet]. 2012. Available from: http://www.ifcc.org/media/218177/IFCC Troponin Tables ng-L Update-December 2012.pdf. Accessed on 23 May, 2014
38. Apple FS. Counterpoint: standardization of cardiac troponin I assays will not occur in my lifetime. Clin Chem 2012;58:169-71.
39. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined - a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000;36:959-69.
40. Thygesen K, Alpert JS, White HD, Jaffe AS, Apple FS, Galvani M, et al. Universal definition of myocardial infarction. Circulation 2007;116:2634-53.
41. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third universal definition of myocardial infarction. Circulation 2012;126:2020-35.
42. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third universal definition of myocardial infarction. J Am Coll Cardiol 2012;60:1581-98.
43. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD. Third universal definition of myocardial infarction. Eur Heart J 2012;33:2551-67.
44. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD. Third universal definition of myocardial infarction. Nat Rev Cardiol 2012;9:620-33.
45. Wiviott SD, Cannon CP, Morrow DA, Murphy SA, Gibson CM, McCabe CH, et al. Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction: a TACTICS-TIMI 18 trial. Circulation 2004;109:580-6.
46. Motiwala SR, Sarma A, Januzzi JL, O'Donoghue ML. Biomarkers in ACS and heart failure: should men and women be interpreted differently? Clin Chem 2014;60:35-43.
47. Bohula May EA, Bonaca MP, Jarolim P, Antman EM, Braunwald E, Giugliano RP, et al. Prognostic performance of a high-sensitivity cardiac troponin I assay in patients with non-ST-elevation acute coronary syndrome. Clin Chem 2014;60:158-64.
48. th percentile value of cardiac troponin. Clin Chem 2014;60:455-62.
49. Conrad MJ, Jarolim P. Cardiac troponins and high-sensitivity cardiac troponin assays. Clin Lab Med 2014;34:59-73.
50. Reichlin T, Irfan A, Twerenbold R, Reiter M, Hochholzer W, Burkhalter H, et al. Utility of absolute and relative changes in cardiac troponin concentrations in the early diagnosis of acute myocardial infarction. Circulation 2011;124:136-45.
51. Mueller M, Biener M, Vafaie M, Doerr S, Keller T, Blankenberg S, et al. Absolute and relative kinetic changes of high-sensitivity cardiac troponin T in acute coronary syndrome and in patients with increased troponin in the absence of acute coronary syndrome. Clin Chem 2012;58:209-18.
52. Apple FS, Morrow DA. Delta cardiac troponin values in practice: are we ready to move absolutely forward to clinical routine? Clin Chem 2012;58:8-10.
53. Fraser CG. Reference change values. Clin Chem Lab Med 2011;50:807-12.
54. Thygesen K, Mair J, Giannitsis E, Mueller C, Lindahl B, Blankenberg S, et al. How to use high-sensitivity cardiac troponins in acute cardiac care. Eur Heart J 2012;33:2252-7.
55. Frankenstein L, Wu AH, Hallermayer K, Wians FH, Giannitsis E, Katus HA. Biological variation and reference change value of high-sensitivity troponin T in healthy individuals during short and intermediate follow-up periods. Clin Chem 2011;57:1068-71.
56. Vasile VC, Saenger AK, Kroning JM, Jaffe AS. Biological and analytical variability of a novel high-sensitivity cardiac troponin T assay. Clin Chem 2010;56:1086-90.
57. Vasile VC, Saenger AK, Kroning JM, Klee GG, Jaffe AS. Biologic variation of a novel cardiac troponin I assay. Clin Chem 2011;57:1080-1.
58. Wu AH, Lu QA, Todd J, Moecks J, Wians F. Short- and long-term biological variation in cardiac troponin I measured with a high-sensitivity assay: implications for clinical practice. Clin Chem 2009;55:52-8.
59. Wu AH, Akhigbe P, Wians F. Long-term biological variation in cardiac troponin I. Clin Biochem 2012;45:714-6.
60. Nordenskjöld AM, Ahlström H, Eggers KM, Fröbert O, Jaffe AS, Venge P, et al. Short- and long-term individual variation in cardiac troponin in patients with stable coronary artery disease. Clin Chem 2013;59:401-9.
61. Mahajan VS, Jarolim P. How to interpret elevated cardiac troponin levels. Circulation 2011;124:2350-4.
62. Than M, Cullen L, Aldous S, Parsonage WA, Reid CM, Greenslade J, et al. 2-Hour accelerated diagnostic protocol to assess patients with chest pain symptoms using contemporary troponins as the only biomarker: the ADAPT trial. J Am Coll Cardiol 2012;59:2091-8.
63. Kavsak PA, Worster A, You JJ, Oremus M, Shortt C, Phan K, et al. Ninety-minute vs 3-h performance of high-sensitivity cardiac troponin assays for predicting hospitalization for acute coronary syndrome. Clin Chem 2013;59:1407-10.
64. Keller T, Zeller T, Ojeda F, Tzikas S, Lillpopp L, Sinning C, et al. Serial changes in highly sensitive troponin I assay and early diagnosis of myocardial infarction. J Am Med Assoc 2011;306:2684-93.
65. Reichlin T, Schindler C, Drexler B, Twerenbold R, Reiter M, Zellweger C, et al. One-hour rule-out and rule-in of acute myocardial infarction using high-sensitivity cardiac troponin T. Arch Intern Med 2012;172:1211-8.
66. Biener M, Mueller M, Vafaie M, Keller T, Blankenberg S, White HD, et al. Comparison of a 3-hour versus a 6-hour sampling-protocol using high-sensitivity cardiac troponin T for rule-out and rule-in of non-STEMI in an unselected emergency department population. Int J Cardiol 2013;167:1134-40.
67. Moeckel M, Searle J, Hamm C, Slagman A, Blankenberg S, Huber K, et al. Instant early rule-out using cardiac troponin and copeptin in low- to intermediate-risk patients with suspected ACS: a prospective, randomized multicenter study for early discharge (BIC-8). ESC Congress, Amsterdam 2013.
68. Thygesen K, Mair J, Giannitsis E, Mueller C, Lindahl B, Blankenberg S, et al. How to use high-sensitivity cardiac troponins in acute cardiac care. Eur Heart J 2012;33:2252-7.
69. Reichlin T, Hochholzer W, Bassetti S, Steuer S, Stelzig C, Hartwiger S, et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med 2009;361:858-67.
70. Keller T, Zeller T, Peetz D, Tzikas S, Roth A, Czyz E, et al. Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med 2009;361:868-77.
71. Jaffe AS, Apple FS. High-sensitivity cardiac troponin: hype, help, and reality. Clin Chem 2010;56:342-4.
72. Mingels AM, Jacobs LH, Kleijnen VW, Laufer EM, Winkens B, Hofstra L, et al. Cardiac troponin T elevations, using highly sensitive assay, in recreational running depend on running distance. Clin Res Cardiol 2010;99:385-91.
73. Zhang J, Kruss S, Hilmer AJ, Shimizu S, Schmois Z, De La Cruz F, et al. A rapid, direct, quantitative, and label-free detector of cardiac biomarker troponin T using near-infrared fluorescent single-walled carbon nanotube sensors. Adv Healthc Mater 2014;3:412-23.
74. Tang L, Casas J, Venkataramasubramani M. Magnetic nanoparticle mediated enhancement of localized surface plasmon resonance for ultrasensitive bioanalytical assay in human blood plasma. Anal Chem 2013;85:1431-9.
75. Lee W, Jung J, Hahn YK, Kim SK, Lee Y, Lee J, et al. A centrifugally actuated point-of-care testing system for the surface acoustic wave immunosensing of cardiac troponin I. Analyst 2013;138:2558-66.
76. Jia P, Jiang H, Sabarinathan J, Yang J. Plasmonic nanohole array sensors fabricated by template transfer with improved optical performance. Nanotechnology 2013;24:195501.
77. Aakre KM, Røraas T, Petersen PH, Svarstad E, Sellevoll H, Skadberg O, et al. Weekly and 90-minute biological variations in cardiac troponin T and cardiac troponin I in hemodialysis patients and healthy controls. Clin Chem 2014;60:838-47.
78. Aakre KM, Sandberg S. Can changes in troponin results be useful in diagnosing myocardial infarction? Clin Chem 2010;56:1047-9.
79. Hamm CW, Ravkilde J, Gerhardt W, Jørgensen P, Peheim E, Ljungdahl L, et al. The prognostic value of serum troponin T in unstable angina. N Engl J Med 1992;327:146-50.
80. Braunwald E, Morrow DA. Unstable angina: is it time for a requiem? Circulation 2013;127:2452-7.
81. Lindahl B, Venge P, Wallentin L. Relation between troponin T and the risk of subsequent cardiac events in unstable coronary artery disease. The FRISC study group. Circulation 1996;93:1651-7.
82. Antman EM, Tanasijevic MJ, Thompson B, Schactman M, McCabe CH, Cannon CP, et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 1996;335:1342-9.
83. James S, Armstrong P, Califf R, Simoons ML, Venge P, Wallentin L, et al. Troponin T levels and risk of 30-day outcomes in patients with the acute coronary syndrome: prospective verification in the GUSTO-IV trial. Am J Med 2003;115:178-84.
84. Daniels LB, Laughlin GA, Clopton P, Maisel AS, Barrett-Connor E. Minimally elevated cardiac troponin T and elevated N-terminal pro-B-type natriuretic peptide predict mortality in older adults: results from the Rancho Bernardo Study. J Am Coll Cardiol 2008;52:450-9.
85. Leistner DM, Klotsche J, Pieper L, Stalla GK, Lehnert H, Silber S, et al. Circulating troponin as measured by a sensitive assay for cardiovascular risk assessment in primary prevention. Clin Chem 2012;58:200-8.
86. Blankenberg S, Zeller T, Saarela O, Havulinna AS, Kee F, Tunstall-Pedoe H, et al. Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project. Circulation 2010;121:2388-97.
87. Vasile VC, Chai H-S, Abdeldayem D, Afessa B, Jaffe AS. Elevated cardiac troponin T levels in critically ill patients with sepsis. Am J Med 2013;126:1114-21.
88. Lamb EJ, Webb MC, Abbas NA. The significance of serum troponin T in patients with kidney disease: a review of the literature. Ann Clin Biochem 2004;41:1-9.
89. DeFilippi C, Seliger SL, Kelley W, Duh S-H, Hise M, Christenson RH, et al. Interpreting cardiac troponin results from high-sensitivity assays in chronic kidney disease without acute coronary syndrome. Clin Chem 2012;58:1342-51.
90. Lamb EJ, Kenny C, Abbas NA, John RI, Webb MC, Price CP, et al. Cardiac troponin I concentration is commonly increased in nondialysis patients with CKD: experience with a sensitive assay. Am J Kidney Dis 2007;49:507-16.
91. Hickman PE, Koerbin G, Southcott E, Tate J, Dimeski G, Carter A, et al. Newer cardiac troponin I assays have similar performance to troponin T in patients with end-stage renal disease. Ann Clin Biochem 2007;44:285-9.
92. Pfeffer MA, Burdmann EA, Chen C-Y, Cooper ME, de Zeeuw D, Eckardt K, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009;361:2019-32.
93. Desai AS, Toto R, Jarolim P, Uno H, Eckardt K-U, Kewalramani R, et al. Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD. Am J Kidney Dis 2011;58:717-28.
94. McMurray JJ, Uno H, Jarolim P, Desai AS, de Zeeuw D, Eckardt K-U, et al. Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT). Am Heart J 2011;162:748-55.
95. Haaf P, Drexler B, Reichlin T, Twerenbold R, Reiter M, Meissner J, et al. High-sensitivity cardiac troponin in the distinction of acute myocardial infarction from acute cardiac noncoronary artery disease. Circulation 2012;126:31-40.
96. Lindahl B, Venge P, James S. The new high-sensitivity cardiac troponin T assay improves risk assessment in acute coronary syndromes. Am Heart J 2010;160:224-9.
97. De Lemos JA, Drazner MH, Omland T, Ayers CR, Khera A, Rohatgi A, et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. J Am Med Assoc 2010;304:2503-12.
98. Giannitsis E, Spanuth E, Horsch A, Kleber ME, Koch W, Grammer TB, et al. High-sensitivity cardiac troponin T and N-terminal pro-B-type natriuretic peptide predict mortality in stable coronary artery disease: results from the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Clin Chem Lab Med 2013;51:2019-28.
99. Lyngbæk S, Winkel P, Gøtze JP, Kastrup J, Gluud C, Kolmos HJ, et al. Risk stratification in stable coronary artery disease is possible at cardiac troponin levels below conventional detection and is improved by use of N-terminal pro-B-type natriuretic peptide. Eur J Prev Cardiol 2013 May 30 [Epub ahead of print].
100. Lindahl B, Eggers KM, Venge P, James S. Evaluation of four sensitive troponin assays for risk assessment in acute coronary syndromes using a new clinically oriented approach for comparison of assays. Clin Chem Lab Med 2013;51:1859-64.
101. DeFilippi CR, de Lemos JA, Christenson RH, Gottdiener JS, Kop WJ, Zhan M, et al. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. J Am Med Assoc 2010;304:2494-502.
102. Gravning J, Askevold ET, Nymo SH, Ueland T, Wikstrand J, McMurray JJ, et al. Prognostic effect of high-sensitive troponin T assessment in elderly patients with chronic heart failure: results from the CORONA trial. Circ Heart Fail 2014;7:96-103.
103. Eggers KM, Al-Shakarchi J, Berglund L, Lindahl B, Siegbahn A, Wallentin L, et al. High-sensitive cardiac troponin T and its relations to cardiovascular risk factors, morbidity, and mortality in elderly men. Am Heart J 2013;166:541-8.
104. Baron JM, Lewandrowski EL, Januzzi JL, Bajwa EK, Thompson BT, Lewandrowski KB. Measurement of high-sensitivity troponin T in noncardiac medical intensive care unit patients. Correlation to mortality and length of stay. Am J Clin Pathol 2014;141:488-93.
105. Wilhelm J, Hettwer S, Schuermann M, Bagger S, Gerhardt F, Mundt S, et al. Elevated troponin in septic patients in the emergency department: frequency, causes, and prognostic implications. Clin Res Cardiol 2014;103:561-7.
106. Sabatine MS, Morrow DA, de Lemos JA, Jarolim P, Braunwald E. Detection of acute changes in circulating troponin in the setting of transient stress test-induced myocardial ischaemia using an ultrasensitive assay: results from TIMI 35. Eur Heart J 2009;30:162-9.
107. Jarolim P, Morrow DA, O'Malley RG, Bonaca MP, Scirica BM, Murphy S, et al. Determination of cardiac troponin with a single-molecule high-sensitivity assay and outcomes in patients with stable coronary artery disease: analysis from PROVE IT-TIMI 22. Annual Meeting of the American Association for Clinical Chemistry, Houston 2013. p S249.
108. Lippi G, Cervellin G. Do we really need high-sensitivity troponin immunoassays in the emergency department? Maybe not. Clin Chem Lab Med 2014;52:205-12.
109. Patel PC, Hill DA, Ayers CR, Lavingia B, Kaiser P, Dyer AK, et al. High-sensitivity cardiac troponin I assay to screen for acute rejection in patients with heart transplant. Circ Heart Fail 2014;7:463-9.
110. DeBeradinis B, Januzzi JL. Use of biomarkers to guide outpatient therapy of heart failure. Curr Opin Cardiol 2012;27:661-8.
111. Ho CY, López B, Coelho-Filho OR, Lakdawala NK, Cirino AL, Jarolim P, et al. Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. N Engl J Med 2010;363:552-63.